IGC Pharma Q3 2026 net loss widens 12% to $2.05 million; revenue rises 72% to $328,000
IGC•IGC Pharma’s third-quarter 2026 net loss attributable to common stockholders widened 12% year over year to approximately $2.05 million, while revenue rose 72% to approximately $328,000. The CALMA Alzheimer’s agitation trial completed enrollment with 170 participants randomized, above its original target of 146.
1. Quarterly results
IGC Pharma reported a third-quarter 2026 net loss attributable to common stockholders of approximately $2.05 million, up 12% year over year. Revenue rose 72% to approximately $328,000, while research and development expenses fell 38% to approximately $1 million, primarily reflecting completion of most CALMA site activation in the first half of 2026.
2. Cash and trial enrollment
Cash totaled approximately $377,000 at September 30, 2026. The company also had access to an undrawn $12 million revolving working capital credit facility, subject to terms. CALMA completed enrollment with 170 participants randomized, exceeding its original target of 146.
